Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Heart failure

SGLT2 inhibitors improve cardiovascular risk

    • Cardiology
    • Congress Reports
    • Endocrinology and Diabetology
    • RX
    • Studies
  • 2 minute read

SGLT2 inhibitors are used with great success as antidiabetic agents. However, new study data revealed a positive side effect: the drug group appears to have additional cardioprotective as well as nephropotective effects. These effects occur independently of the presence of diabetes mellitus. Presented results include evidence of reduced clinical events in chronic heart failure.

Recent study results presented at the congress on the treatment ofheart failuredemonstrate a reduction in the risk of cardiovascular death or hospitalization for SGLT2 inhibitors in heart failure with decreased ejection fraction compared with placebo. It is irrelevant whether the patient has diabetes mellitus or not. Experts agree that the now compelling evidence supports adding SGLT2 inhibitors to the therapies recommended for this condition.

The EMPEROR-Reduced study evaluated 3730 patients with mild, moderate, or severe chronic heart failure and reduced ejection fraction. Only half of the included patients suffered from concomitant diabetes mellitus. Randomization was performed in a 1:1 ratio. The serum group received empagliflozin 10 mg once daily, and the other group received placebo. The primary study end point was a composite end point of cardiovascular death and hospitalization for heart failure. Secondary end points included total hospitalizations after first and recurrent heart failure and the decline in glomerular filtration rate over time.

Significant risk reduction achieved

A significant 25% reduction in the risk of cardiovascular-related death and hospitalization for heart failure was achieved. Especially the relative reduction of hospitalizations (first events) due to heart failure with 31% is convincing. For cardiovascular mortality, there was a relative decrease of 8% with empagliflozin (10.0% vs.10.8%, HR: 0.92; 95% CI: 0.75-1.12).

The SGLT2 inhibitor was also beneficial with regard to renal function: the decline in glomerular filtration rate in the second secondary endpoint was also significantly slowed within 16 months compared with placebo: -4.2 ml/min/1.73 m2 with placebo versus -0.9 ml/min/1.73 m2 with empagliflozin. In addition, patients treated with empagliflozin showed a lower risk of severe renal events.

Extension of the therapy management

The experts therefore advocate adding SGLT2 inhibitors to the treatment options for heart failure patients with and without diabetes and reduced ejection fraction. This requirement is supported by further positive study results. For example, a subgroup analysis demonstrated that empagliflozin not only led to weight loss in patients with acute myocardial infarction and type 2 diabetes, but also reduced intracellular, extracellular, and total body water. In addition, add-on therapy with the SGLT2 inhibitor has been shown to reduce transtubular potassium gradient (TTKG) in type 2 diabetic patients hospitalized for acute decompensated heart failure (ADHF). TTKG is associated with poor prognosis in ADHF patients.

Source: ESC 2020

 

Further reading:

  • Packer M, et al: New Engl J Med 2020; DOI: 10.1056/NEJMoa2022190
  • Hoshika Y, et al: effect of empagliflozin versus placebo in body composition in pateints with acute myocardial infarction and type 2 diabetes mellitus: subgroup analysis oft he EMBODY trial. ESC 2020
  • Tamaki S, et al: Effect of empagliflozin as add-on therapy on transtubular potassium concentration gradident patients with type 2 diabetes hospitalized for acute decompensated heart failure. ESC 2020

 

CARDIOVASC 2020; 19(4): 22 (published 7/12/20, ahead of print).

Autoren
  • Leoni Burggraf
Publikation
  • CARDIOVASC
Related Topics
  • Diabetes mellitus
  • Heart failure
  • SGLT2
Previous Article
  • Gastrointestinal tumors

Latest scientific findings and real-life data

  • Congress Reports
  • Gastroenterology and Hepatology
  • Oncology
  • RX
  • Studies
View Post
Next Article
  • Moderate and severe plaque psoriasis

From Immunopathogenesis to Highly Effective Therapies – Enduring Lesion Freedom as the Goal

  • Congress Reports
  • Dermatology and venereology
  • Genetics
  • Rheumatology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 5 min
  • Type 2 diabetes

Pharmacotherapy can lead to remission

    • Education
    • Endocrinology and Diabetology
    • Nutrition
    • Pharmacology and toxicology
    • RX
View Post
  • 4 min
  • Case Report

Mycosis fungoides in an 11-year-old child

    • Allergology and clinical immunology
    • Cases
    • Dermatology and venereology
    • Education
    • Oncology
    • Pediatrics
    • RX
    • Studies
View Post
  • 6 min
  • EHA 2025

Progress in multiple myeloma

    • Congress Reports
    • Hematology
    • Oncology
    • RX
    • Studies
View Post
  • 6 min
  • Interstitial lung diseases

Artificial intelligence improves ILD diagnosis

    • Education
    • General Internal Medicine
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 7 min
  • Management of patients after alloHCST

ERS/EBMT guideline recommendations on pulmonary cGvHD

    • Education
    • General Internal Medicine
    • Genetics
    • Hematology
    • Pneumology
    • RX
    • Studies
View Post
  • 6 min
  • From early intervention to individualization

The new guidelines at a glance

    • Cardiology
    • Congress Reports
    • RX
    • Studies
View Post
  • 3 min
  • Pyoderma gangraenosum

New study data confirm the validity of the PARACELSUS score

    • Congress Reports
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Geriatrics
    • Orthopedics
    • Prevention and health care
    • RX
    • Studies
    • Surgery
View Post
  • 8 min
  • Progressive multiple sclerosis

New horizons: from BTK inhibitors to remyelination

    • Education
    • Genetics
    • Neurology
    • RX
    • Studies
Top Partner Content
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Colorectal cancer screening – an update
  • 2
    Yellow nail and Swyer-James syndrome
  • 3
    Individual therapy management for an optimized outcome – an update
  • 4
    Doing sport without fear or risk
  • 5
    UV protection and skin cancer screening – Update 2025

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.